Login / Signup

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.

Krzysztof Piotr MalinowskiPaweł KawalecWojciech TrąbkaChristoph SowadaGuenka PetrovaManoela ManovaAlexandra SavovaPero DraganićJuraj SlabýAgnes MännikKristóf MárkyZinta RugajaJolanta GulbinovicTomas TesarMarian Sorin Paveliu
Published in: Orphanet journal of rare diseases (2020)
In Hungary, Latvia, and Slovakia, a positive recommendation was associated with a reimbursement, and a negative one, with the lack of reimbursement. The reimbursement of oncology OD is associated with a growing burden for public budget, and the expenses are correlated with the total GDP. The highest share of drugs with any recommendation was observed in Poland, and the lowest, in Latvia and Romania. The share of reimbursed drugs was the lowest in Latvia and the highest in Poland.
Keyphrases
  • healthcare
  • public health
  • mental health
  • palliative care
  • south africa
  • drug induced
  • emergency department
  • risk factors
  • social media
  • human health